Type I interferon induces CXCL13 to support ectopic germinal center formation.
Animals
B-Lymphocytes
/ metabolism
Chemokine CXCL13
/ genetics
Female
Fibroblasts
/ metabolism
Germinal Center
/ drug effects
Interferon Type I
/ metabolism
Interferon-beta
/ pharmacology
Lung
/ metabolism
Male
Mice, Inbred C57BL
Mice, Transgenic
Orthomyxoviridae Infections
/ metabolism
Receptors, CXCR5
/ genetics
T-Lymphocytes, Regulatory
/ metabolism
Journal
The Journal of experimental medicine
ISSN: 1540-9538
Titre abrégé: J Exp Med
Pays: United States
ID NLM: 2985109R
Informations de publication
Date de publication:
04 03 2019
04 03 2019
Historique:
received:
28
06
2018
revised:
05
12
2018
accepted:
17
01
2019
pubmed:
7
2
2019
medline:
24
3
2020
entrez:
7
2
2019
Statut:
ppublish
Résumé
Ectopic lymphoid structures form in a wide range of inflammatory conditions, including infection, autoimmune disease, and cancer. In the context of infection, this response can be beneficial for the host: influenza A virus infection-induced pulmonary ectopic germinal centers give rise to more broadly cross-reactive antibody responses, thereby generating cross-strain protection. However, despite the ubiquity of ectopic lymphoid structures and their role in both health and disease, little is known about the mechanisms by which inflammation is able to convert a peripheral tissue into one that resembles a secondary lymphoid organ. Here, we show that type I IFN produced after viral infection can induce CXCL13 expression in a phenotypically distinct population of lung fibroblasts, driving CXCR5-dependent recruitment of B cells and initiating ectopic germinal center formation. This identifies type I IFN as a novel inducer of CXCL13, which, in combination with other stimuli, can promote lung remodeling, converting a nonlymphoid tissue into one permissive to functional tertiary lymphoid structure formation.
Identifiants
pubmed: 30723095
pii: jem.20181216
doi: 10.1084/jem.20181216
pmc: PMC6400543
doi:
Substances chimiques
CXCR5 protein, mouse
0
Chemokine CXCL13
0
Cxcl13 protein, mouse
0
Interferon Type I
0
Receptors, CXCR5
0
Interferon-beta
77238-31-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
621-637Subventions
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/D/20002174
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/B/000C0407
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/N011740/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/F019726/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BBS/E/B/000C0427
Pays : United Kingdom
Informations de copyright
© 2019 Denton et al.
Références
Lancet. 2011 Dec 3;378(9807):1917-30
pubmed: 22078723
Future Virol. 2011 Aug;6(8):951-962
pubmed: 21909336
J Exp Med. 2014 Apr 7;211(4):643-51
pubmed: 24663215
J Virol. 2010 Aug;84(15):7613-24
pubmed: 20504916
Nat Immunol. 2012 Nov;13(11):1092-100
pubmed: 23001146
BMC Immunol. 2015 Feb 12;16:6
pubmed: 25879435
Nat Immunol. 2012 Nov;13(11):1083-91
pubmed: 23001145
Cell. 1999 Oct 1;99(1):23-33
pubmed: 10520991
Mucosal Immunol. 2010 Nov;3(6):537-44
pubmed: 20811344
Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10577-82
pubmed: 17563386
J Exp Med. 2015 Sep 21;212(10):1709-23
pubmed: 26324444
Nature. 2014 Oct 23;514(7523):498-502
pubmed: 25341788
Viral Immunol. 2017 Jul/Aug;30(6):431-437
pubmed: 28661720
Proc Natl Acad Sci U S A. 2015 Sep 1;112(35):11024-9
pubmed: 26286991
J Clin Invest. 2006 Dec;116(12):3183-94
pubmed: 17143328
Front Immunol. 2012 Dec 14;3:381
pubmed: 23248630
J Immunol. 2012 Sep 15;189(6):2702-6
pubmed: 22896631
Immunity. 2006 Oct;25(4):643-54
pubmed: 17045819
Annu Rev Immunol. 2016 May 20;34:335-68
pubmed: 26907215
Front Immunol. 2016 Jun 30;7:258
pubmed: 27446088
Front Immunol. 2016 Aug 16;7:312
pubmed: 27579026
Nat Rev Immunol. 2014 Jul;14(7):447-62
pubmed: 24948366
J Virol. 2017 Apr 28;91(10):
pubmed: 28275192
Exp Cell Res. 2011 Mar 10;317(5):620-31
pubmed: 21376175
Immunity. 2009 May;30(5):731-43
pubmed: 19427241
Curr Opin Immunol. 2017 Apr;45:103-111
pubmed: 28319729
N Engl J Med. 2004 Jun 24;350(26):2645-53
pubmed: 15215480
J Immunol. 2018 Nov 1;201(9):2641-2653
pubmed: 30282750
Nat Immunol. 2011 Jun 12;12(7):639-46
pubmed: 21666689
J Immunol. 2007 Dec 1;179(11):7448-56
pubmed: 18025189
Rheumatology (Oxford). 2017 Oct 1;56(10):1662-1675
pubmed: 28122959
Cell Rep. 2017 Apr 18;19(3):461-470
pubmed: 28423310
Curr Opin Rheumatol. 2013 Mar;25(2):248-53
pubmed: 23249830
Immunity. 2016 Dec 20;45(6):1299-1310
pubmed: 28002730
J Exp Med. 2016 Nov 14;213(12):2527-2538
pubmed: 27821552
Nature. 2008 Oct 9;455(7214):764-9
pubmed: 18843362
J Exp Med. 2011 Nov 21;208(12):2497-510
pubmed: 22042977
Nat Immunol. 2015 Aug;16(8):819-828
pubmed: 26147686
Nat Immunol. 2014 Oct;15(10):973-81
pubmed: 25151489
J Exp Med. 2003 Apr 7;197(7):845-60
pubmed: 12668643
Immunity. 2015 Sep 15;43(3):579-90
pubmed: 26341400
Eur J Immunol. 2008 Feb;38(2):342-9
pubmed: 18196519
Immunity. 2017 Jul 18;47(1):80-92.e4
pubmed: 28709801
Nat Med. 2004 Sep;10(9):927-34
pubmed: 15311275
Vaccine. 2018 May 31;36(23):3199-3207
pubmed: 29716771
PLoS One. 2012;7(7):e41169
pubmed: 22815957
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):12139-44
pubmed: 25092322
Cell. 1996 Dec 13;87(6):1037-47
pubmed: 8978608
Am J Respir Crit Care Med. 2009 May 1;179(9):799-805
pubmed: 19218194
Methods Mol Biol. 2015;1291:103-23
pubmed: 25836305
Cell Tissue Res. 2011 Jan;343(1):13-21
pubmed: 20848130
Immunity. 2018 Feb 20;48(2):313-326.e5
pubmed: 29396161
PLoS Pathog. 2011 Feb;7(2):e1001304
pubmed: 21383977
J Exp Med. 2002 Jul 1;196(1):65-75
pubmed: 12093871
Proc Natl Acad Sci U S A. 2012 Feb 14;109(7):2485-90
pubmed: 22308386